KD U593
Alternative Names: KD-U593; KD-U5934thLatest Information Update: 19 May 2021
At a glance
- Originator Nanjing KAEDI Biotech
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 May 2021 KD U593 is available for licensing as of 12 May 2021. http://www.cartbiomed.com/index.php?m=content&c=index&a=lists&catid=20
- 12 May 2021 Early research in Cancer in China (Parenteral) before May 2021 (Nanjing KAEDI Biotech pipeline, May 2021)
- 12 May 2021 Preclinical trials in Cancer in China (Parenteral) before May 2021 (Nanjing KAEDI Biotech pipeline, May 2021)